Shanrong Biotechnology Corp. (SRBT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.39: the stock has moved about 61% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerShanrong Biotechnology Corp. (SRBT) trades at $0.0001. Shanrong Biotechnology Corp. operates as a project management and executive consulting company, focusing on defense, homeland security, and telecommunications markets. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for SRBT: SRBT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Shanrong Biotechnology Corp. (SRBT) Financial Services Profile
Shanrong Biotechnology Corp., formerly Defense Solutions Holding, operates as a project management and executive consulting firm within the shell companies industry. The company focuses on defense, homeland security, and telecommunications, offering services such as armored vehicle upgrades, maintenance, and training. It faces challenges inherent to OTC-listed shell companies.
What Is the Investment Thesis for SRBT?
Investing in Shanrong Biotechnology Corp. presents a speculative opportunity, given its OTC listing and shell company classification. The company's focus on defense and security-related services, including armored vehicle upgrades and training, could provide revenue streams, but its financial performance and disclosure status are unclear. With a market capitalization of $0.00B and a negative P/E ratio of -0.01, the company's valuation is difficult to assess. A beta of 0.39 suggests low volatility relative to the market. Growth catalysts may include securing new contracts in the defense or security sectors, but potential risks include limited liquidity, disclosure requirements, and the inherent risks associated with shell companies. Investors should conduct thorough due diligence and consider the speculative nature of this investment.
Based on FMP financials and quantitative analysis
SRBT Key Highlights
Market Cap of $0.00B indicates a micro-cap company with limited financial resources.
- P/E Ratio of -0.01 reflects negative earnings, suggesting the company is not currently profitable.
- Beta of 0.39 suggests the stock is less volatile than the overall market.
- No Dividend Yield indicates that the company does not distribute profits to shareholders.
- OTC Other tier listing implies higher risk and less stringent regulatory oversight compared to major exchanges.
Who Are SRBT's Competitors?
SRBT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CIIT Tianci International, Inc. | $2.58 | +4.03% | 32 5-pillar | |
| COLA Columbus Acquisition Corp | $2.86 | -60.82% | $12.9M | 44 5-pillar |
| ASPC A SPAC III Acquisition Corp. | $10.81 | -0.16% | $25.3M | 47 5-pillar |
| RIBB Ribbon Acquisition Corp | $7.40 | -7.04% | $36.2M | 42 5-pillar |
| BKHA Black Hawk Acquisition Corporation | $12.28 | -0.81% | $51.4M | 47 5-pillar |
| IBAC IB Acquisition Corp. | $10.88 | -0.18% | $54.5M | 43 5-pillar |
| FVN Future Vision II Acquisition Corp. | $8.87 | +10.81% | $60.4M | 42 5-pillar |
| WTG Wintergreen Acquisition Corp. | $10.99 | +3.29% | $77.7M | 50 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SRBT's Key Strengths?
Expertise in armored vehicle upgrades and maintenance.
- Experience in defense and homeland security markets.
- Proprietary training programs.
- Established relationships with military and police forces.
What Are SRBT's Weaknesses?
OTC listing indicates higher risk and less liquidity.
- Limited financial resources.
- Shell company classification raises concerns about transparency.
- Dependence on government contracts.
What Are the Key Risks for SRBT?
Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- OTC listing indicates higher risk and less liquidity.
- Increased regulatory scrutiny of shell companies.
- Competition from larger defense contractors.
- Economic downturn affecting government spending.
- Geopolitical instability.
What Are SRBT's Competitive Advantages?
- Specialized expertise in armored vehicle upgrades.
- Established relationships with military and police forces.
- Proprietary training programs for vehicle maintenance and operation.
- Experience in defense and homeland security markets.
What Does SRBT Do?
Shanrong Biotechnology Corp., based in Beverly Hills, California, operates as a project management and executive consulting company. Originally known as Defense Solutions Holding, Inc., the company rebranded in September 2017 to Shanrong Biotechnology Corp. The company's core business revolves around providing services and solutions to the defense, homeland security, information technology, and telecommunications markets. These services include program management, business development, and strategic studies and analyses. A significant aspect of Shanrong Biotechnology's operations involves refurbishing and upgrading armored vehicles with advanced digital communications systems. In addition to these upgrades, the company supplies spare parts and equipment for military and police forces. To support the use and maintenance of these vehicles, Shanrong Biotechnology offers a range of training services, including onsite maintenance training, operator training, and tactical training. The company's evolution reflects a strategic shift towards integrating biotechnology into its existing defense and security-related services, although the extent of its biotechnology activities is not detailed in available information. This transition positions Shanrong Biotechnology as a hybrid entity, aiming to leverage its expertise in defense and security with potential opportunities in the biotechnology sector.
What Products and Services Does SRBT Offer?
- Provides project management services.
- Offers executive consulting services.
- Refurbishes and upgrades armored vehicles with digital communications.
- Supplies spare parts and equipment for military and police forces.
- Offers onsite maintenance and maintenance training.
- Provides operator and tactical training services.
- Conducts program management and business development.
- Performs strategic studies and analyses in defense, homeland security, IT, and telecommunications.
How Does SRBT Make Money?
- Generates revenue through project management fees.
- Earns income from executive consulting services.
- Profits from the sale of refurbished and upgraded armored vehicles.
- Revenue from supplying spare parts and equipment.
- Income from maintenance and training services.
What Industry Does SRBT Operate In?
Shanrong Biotechnology Corp. operates within the shell companies industry, a segment of the financial services sector characterized by companies with limited operations and assets. The industry is highly speculative and subject to regulatory scrutiny due to the potential for fraud and manipulation. Companies in this sector often seek to merge with or acquire other businesses to gain operational status. The competitive landscape includes other shell companies like CAMG, CCWF, FBDS, GYGC, and ILST, all vying for opportunities to transform their business models. Market trends include increased regulatory oversight and investor caution due to past instances of fraudulent activities.
Who Are SRBT's Key Customers?
- Military forces.
- Police forces.
- Government agencies.
- Defense contractors.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Shanrong Biotechnology Corp. stands at 6.4%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -77.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Shanrong Biotechnology Corp. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Torrance, US. The company is led by CEO Colonel Timothy D. Ringgold. SRBT has traded publicly since 2018.
Financial Health
Shanrong Biotechnology Corp.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
SRBT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
SRBT Latest News
No recent news available for SRBT.
SRBT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SRBT.
Price Targets
Wall Street price target analysis for SRBT.
SRBT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SRBT; grades run from A+ (80-100) to F (below 30).
Leadership: Colonel Timothy D. Ringgold
CEO
Colonel Timothy D. Ringgold brings a wealth of experience to Shanrong Biotechnology Corp., primarily stemming from his distinguished military career. His background encompasses leadership roles within defense and security sectors, providing him with a deep understanding of the company's target markets. Ringgold's expertise likely includes strategic planning, program management, and business development within the defense industry. His military background suggests a strong emphasis on discipline, operational efficiency, and risk management, qualities that could be beneficial in guiding Shanrong Biotechnology Corp.
Track Record: Information regarding Colonel Ringgold's specific achievements and strategic decisions at Shanrong Biotechnology Corp. is limited. However, his leadership is presumably focused on leveraging the company's expertise in armored vehicle upgrades and training to secure government contracts and expand its service offerings. Further information is needed to assess his track record in driving growth and profitability at the company.
SRBT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by the least stringent listing requirements and the highest level of risk. Companies in this tier often have limited financial information available and may not meet the minimum qualifications for higher tiers like OTCQB or OTCQX. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous reporting standards and corporate governance requirements. This lack of oversight increases the potential for fraud and manipulation, making it crucial for investors to exercise extreme caution.
- OTC Tier: OTC Other
- Limited liquidity due to OTC listing.
- Lack of transparency and financial disclosure.
- Higher potential for fraud and manipulation.
- Shell company classification raises concerns about legitimacy.
- Dependence on government contracts.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and revenue streams.
- Evaluate the company's competitive position and market opportunities.
- Determine the company's compliance with regulatory requirements.
- Consult with a financial advisor to assess the risks and potential rewards.
- Investigate the company's history and any past legal or regulatory issues.
- CEO with a military background may indicate some level of operational discipline.
- Focus on defense and security-related services suggests a potential market niche.
- Company has been in operation since at least 2017.
- Headquarters in Beverly Hills, CA provides a physical address.
What Investors Ask About Shanrong Biotechnology Corp. (SRBT) — Financials
What do analysts say about SRBT stock?
As of 2026-03-17, there is no available analyst coverage or consensus for Shanrong Biotechnology Corp. (SRBT) due to its OTC listing and limited financial disclosure. Key valuation metrics such as price targets and earnings estimates are not available. Investors should conduct their own independent research and consider the speculative nature of this investment.
What are the main risks for SRBT?
The main risks for Shanrong Biotechnology Corp. (SRBT) include its OTC listing, which indicates higher risk and less liquidity compared to major exchanges.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial information available for Shanrong Biotechnology Corp.
- OTC listing indicates higher risk and less liquidity.
- Shell company classification raises concerns about transparency.